[Anti-amnesic effects of sigma (sigma)-receptor agonists].
Both traditional and novel sigma (sigma)-receptor agonists have been reported to possess anti-amnesic effects in rodents. In particular, the anti-amnesic effects induced by the novel sigma1-receptor agonists, such as (+)-pentazocine, SA4503 and PRE-084, were shown in beta amyloid-peptide-induced, basal forebrain (BF)-lesioned and carbon monoxide (CO)-induced amnesia models and senescence-accelerated mouse (SAM). In addition, these sigma1-receptor agonists have good profiles for the central acetylcholine and dopamine systems. Moreover, they also have neuroprotective and anti-depressive effects. These evidence suggested that the sigma1-receptor agonists may be promising compounds for the treatment of dementing disorders such as Alzheimer's disease, senile dementia and vascular dementia. However, the sigma-receptor family is still considered to be enigmatic molecular targets. More molecular cloning and biochemical studies on the sigma-receptor family are needed.
Matsuno
K
K
Discovery Research Division, Santen Pharmaceutical Co., Ltd., Osaka, Japan.
D000109:Acetylcholine / Q000378:metabolism; D000647:Amnesia / Q000188:drug therapy*; D000818:Animals; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D008024:Ligands; D051379:Mice; D009025:Morpholines / Q000494:pharmacology / Q000627:therapeutic use; D010423:Pentazocine / Q000494:pharmacology / Q000627:therapeutic use; D010620:Phenazocine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D017480:Receptors, sigma / Q000819:agonists* / Q000502:physiology; D000097605:Sigma-1 Receptor
D000109:Acetylcholine; D004298:Dopamine; D008024:Ligands; D009025:Morpholines; D010423:Pentazocine; D010620:Phenazocine; D010879:Piperazines; D017480:Receptors, sigma; D000097605:Sigma-1 Receptor; C071738:2-(4-morpholino)ethyl-1-phenylcyclohexane-1-carboxylate; C012134:SK&F 10047; C101789:SA 4503